Arthrosi Therapeutics Kicks Off Phase 3 REDUCE 1 Trial for Gout Treatment with First Patient Dosed Arthrosi Therapeutics has commenced its pivotal Phase 3 REDUCE 1 trial of AR882 for gout treatment, marking a significant milestone in gout therapy advancements.

Arthrosi Therapeutics Kicks Off Phase 3 REDUCE 1 Trial for Gout Treatment with First Patient Dosed #United_States #San_Diego #Arthrosi_Therapeutics #AR882 #Gout_Treatment

Arthrosi Therapeutics Marks Milestone with Completion of REDUCE 2 Trial Enrollment for Gout Treatment Arthrosi Therapeutics has finished enrolling participants for the REDUCE 2 trial of AR882, a promising gout treatment aimed at improving lives through effective management of uric acid levels and tophi.

Arthrosi Therapeutics Marks Milestone with Completion of REDUCE 2 Trial Enrollment for Gout Treatment #USA #San_Diego #Arthrosi_Therapeutics #AR882 #gout

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trial with AR882 Arthrosi Therapeutics has successfully enrolled over 50% of patients in its Phase 3 REDUCE 2 trial for AR882, a promising treatment for gout. The study aims to redefine patient care and improve the quality of life.

Arthrosi Therapeutics Achieves Major Milestone in Gout Treatment Trial with AR882 #United_States #San_Diego #Arthrosi_Therapeutics #AR882 #Gout_Treatment

Arthrosi Therapeutics Welcomes Dr. John Leaman to Board of Directors Arthrosi Therapeutics has announced the appointment of Dr. John Leaman as an Independent Director on its Board, enhancing its leadership as it advances its gout treatment.

Arthrosi Therapeutics Welcomes Dr. John Leaman to Board of Directors #USA #San_Diego #Arthrosi_Therapeutics #John_Leaman #AR882